Literature DB >> 15116050

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?

Richard B Kim1.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15116050     DOI： 10.1016/j.clpt.2004.01.004

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  9 in total

Review 1.  Pharmacogenomics: challenges and opportunities.

Authors:  Dan M Roden; Russ B Altman; Neal L Benowitz; David A Flockhart; Kathleen M Giacomini; Julie A Johnson; Ronald M Krauss; Howard L McLeod; Mark J Ratain; Mary V Relling; Huijun Z Ring; Alan R Shuldiner; Richard M Weinshilboum; Scott T Weiss
Journal:  Ann Intern Med       Date:  2006-11-21       Impact factor: 25.391

Review 2.  Pharmacogenetics in drug regulation: promise, potential and pitfalls.

Authors:  Rashmi R Shah
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

Review 3.  Drug transporters in pharmacokinetics.

Authors:  Ernst Petzinger; Joachim Geyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-11       Impact factor: 3.000

Review 4.  Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.

Authors:  Kari T Kivistö; Mikko Niemi
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

5.  SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.

Authors:  Wei Zhang; Bi-Lian Chen; Vural Ozdemir; Yi-Jing He; Gan Zhou; Dao-Di Peng; Sheng Deng; Qi-Ying Xie; Wei Xie; Lin-Yong Xu; Lian-Ci Wang; Lan Fan; An Wang; Hong-Hao Zhou
Journal:  Br J Clin Pharmacol       Date:  2007-04-18       Impact factor: 4.335

Review 6.  Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.

Authors:  Pertti J Neuvonen; Janne T Backman; Mikko Niemi
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.

Authors:  Annika Bernsdorf; Thomas Giessmann; Christiane Modess; Danilo Wegner; Stefanie Igelbrink; Ute Hecker; Sierk Haenisch; Ingolf Cascorbi; Bernd Terhaag; Werner Siegmund
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

8.  Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects.

Authors:  Yun Kim; Seonghae Yoon; Yewon Choi; Seo Hyun Yoon; Joo-Youn Cho; In-Jin Jang; Kyung-Sang Yu; Jae-Yong Chung
Journal:  Sci Rep       Date:  2019-12-19       Impact factor: 4.379

9.  Integrative Data Mining, Scaffold Analysis, and Sequential Binary Classification Models for Exploring Ligand Profiles of Hepatic Organic Anion Transporting Polypeptides.

Authors:  Alžběta Türková; Sankalp Jain; Barbara Zdrazil
Journal:  J Chem Inf Model       Date:  2018-11-08       Impact factor: 4.956
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.